Drugs / 90Y-BC8-DOTA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01503242 | Jan 2012 → Jun 2017 | plasma cell myeloma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01921387 | Oct 2013 → Jul 2017 | Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, mantle cell lymphoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90Y-BC8-DOTA | “A Phase I Study of 90Y-BC8-DOTA Monoclonal Antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma” NCT01503242 ↗1“90Y-BC8-DOTA (yttrium Y 90 anti-CD45 monoclonal antibody BC8)” NCT01921387 ↗ |
| Known as | 90Y-BC8 Ab | “OUTLINE: This is a dose-escalation study of yttrium Y 90 anti-CD45 monoclonal antibody BC8 (90Y-BC8 Ab).” NCT01503242 ↗ |
| Modality | Monoclonal antibody | “90Y-BC8-DOTA Monoclonal Antibody” NCT01503242 ↗ |
| Route | Intravenous | “Patients receive 90Y-BC8 Ab intravenously (IV) on day -12” NCT01503242 ↗ |